NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline

Despite modern surgical and medical treatments, breast cancer can re-occur and lead 20% of patients to death. During the last 20 years, pre-clinical studies have shown that treatment failures may be due to the presence of a sub-type of cancer cells, the cancer stem cells, which are resistant to chemotherapy and radiotherapy. By chance, doxycycline, an old, inexpensive and safe molecule seems to target effectively these cancer stem cells. This study proposes to check for the clinical efficacy of doxycycline to target the cancer stem cells and improve the response to neoadjuvant chemotherapy in

Trial Details

NCT ID
NCT06452394
Phase
PHASE2
Sponsor
Swiss Cancer Institute
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Doxycyclin
Locations (sample)
  • Sankt Gallen, Canton of St. Gallen, Switzerland|47.42391,9.37477
  • Genolier, Canton of Vaud, Switzerland|46.43537,6.21809
  • Winterthur, Canton of Zurich, Switzerland|47.50564,8.72413
  • Chur, Kanton Graubünden, Switzerland|46.84986,9.53287
  • Aarau, Switzerland|47.39254,8.04422

Key Eligibility Criteria

  • Written informed consent according to Swiss law and current ICH GCP E6 regulations before registration and prior to any trial specific procedures.
  • Histologically confirmed ER+/HER2- primary invasive breast cancer, according to ASCO/CAP Guideline1,2, defined as ER expression rate ≥ 1%.
  • Patients are candidate for curative surgery and with a tumor size of at least 2 cm and nodal classification cN0-3 according to the 8th edition, Jan…
  • Patients with multiple synchronous ipsilateral tumors are allowed, as long as all lesions are ER+/HER2-. Only one target lesion will be considered …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →